Two Alzheimer’s disease risk genes increase entorhinal cortex volume in young adults

Amanda Marie DiBattista¹, Benson W. Stevens¹², G. William Rebeck¹ and Adam E. Green²*

¹ Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA
² Department of Psychology, Georgetown University, Washington, DC, USA

INTRODUCTION

Multiple genetic polymorphisms have been shown to increase Alzheimer’s disease (AD) risk without guaranteeing its onset (Bertram et al., 2007). Though the mechanisms of genetic risk are largely unknown, one possibility is that risk gene-dependent vulnerabilities and age-dependent vulnerabilities may interact to trigger neurodegeneration (Risacher et al., 2010; Reinvang et al., 2013). Genome-wide association studies have repeatedly shown that the ε4 allele of the apolipoprotein E (APOE) gene is the strongest known genetic risk factor for AD, increasing risk by 200–300% and decreasing age of onset, in a dose-dependent manner (Farrer et al., 1997; Bertram et al., 2007; Harold et al., 2009; Fei and Jianhua, 2013). A related risk factor, apolipoprotein J (APOJ, also known as clusterin, CLU), also modestly increases AD risk, with the APOJ-C risk allele increasing AD risk by 10–15% (Harold et al., 2009; Lambert et al., 2009).

These two AD risk genes encode similar proteins that associate with lipoproteins in the brain (Koch et al., 2001; Elliott et al., 2010) to interact with a shared family of cell surface receptors (Kounnas et al., 1995; Leeb et al., 2014) that promote neurite outgrowth (Nathan et al., 1994; Kang et al., 2005), cholesterol metabolism (for review, see Holtzman et al., 2012), and clearance of the AD pathological hallmark, amyloid-β (Demattos et al., 2004).

Apolipoprotein E genotype is associated with accelerated atrophy in the brain during disease progression (Shen et al., 2010), and the gray matter density in the medial temporal lobe (MTL) of APOE-ε4 carriers is particularly sensitive to this type of atrophy (Thomann et al., 2008; Fei and Jianhua, 2013). While the effect of APOE genotype on MTL atrophy has been well established in older adults, effects on the young brain are less clear. Whole brain analyses in healthy APOE-ε4 carriers report increased (Alexander et al., 2012), decreased (Wishart et al., 2006; O’Dwyer et al., 2012; Knickmeyer et al., 2013), or unchanged (Mondadori et al., 2007; Filippini et al., 2009; Dennis et al., 2010; Samuraki et al., 2012; Stein et al., 2012; Matura et al., 2014) MTL volume depending on the experimental parameters. Although less studied than APOE-ε4, APOJ was also not associated with MTL differences in a large scale genome-wide association study (GWAS) meta-analysis (Stein et al., 2012). As with APOE, it may be that more sensitive analyses are necessary to detect differences induced by APOJ risk. Thus, our aim was to assay gray matter volume in a particular area of the MTL that is susceptible to AD pathology very early in the disease, the entorhinal cortex (Braak et al., 2011). The entorhinal cortex facilitates communication between the hippocampus and neocortex for memory consolidation. We sought to test whether APOE and APOJ genotypes affected entorhinal cortex volume in a cohort of young adults. In addition, the putative functional similarities between the proteins these genes encode (Kounnas et al., 1995; Koch et al., 2001; Elliott et al., 2010; Leeb et al., 2014) prompted us to explore whether APOE and APOJ polymorphisms may have a cumulative effect, which would suggest the potential of a common pathway for these risk factors in a region critical for AD pathogenesis.
MATERIALS AND METHODS

PARTICIPANTS
Participants were healthy, right-handed university students and community members (n = 57, 33 male, 74% Caucasian). Each participant provided informed consent for MRI and genotyping. These participants ranged from 18–35 years of age (mean = 21.8, standard deviation = 4.0) with no history of mental illness, psychoactive medication or brain injury. All procedures received IRB approval prior to the study.

GENOTYPING
We performed genotyping of the human APOJ (or CLU) polymorphism at rs11136000, human APOE polymorphism at rs429358 (codon 112), and human APOE polymorphism at rs7412 (codon 158) using the TaqMan assay (Applied Biosystems). A reaction volume of 25 µL containing 50 ng DNA, 5 mM MgCl2 and 1X TaqMan Universal PCR Master Mix containing AmpliTaq Gold DNA Polymerase was amplified using 40 cycles of 15 s at 95°C and 1 min at 60°C. A total of 0.2 µM of each of the sequence-specific probes 5′-FAM ACCAAAGCCACACCACTATACAA [C]TCTCT CAACCGGGCTCGACTTGA-TAMRA-3′ and 5′-VIC-ACCAAGGCA CACACGATATACAAA[C]TCTCTAACGG GCCC TTGCCACTTGA-TAMRA-3′ were used in the allelic discrimination assay for APOE. For the allelic discrimination assay for APOE, sequence specific probes were also used: 5′ VICTGC CGACCTGCAGAGGCCTGGCAGTGT ACCAGGCCGGGGC–TAMRA-3′ and 5′ VIC-GCTGGGCGCGGACATGGAGGACGTG AAGGACCTGTG[GAGGC CCGCCTCGGATGACCAGCGCCGG GCTAMRA-3′ for rs7412 and 5′ VICTGC CGACCTGCAGAGGCCTGGCAGTGT ACCAGGCCGGGGC–TAMRA-3′ and 5′-FAM-GCTGGGCGCGGACATGGAGGACGTG AAGGACCTGTG[GAGGC CCGCCTCGGATGACCAGCGCCGG GCTAMRA-3′ for rs429358. Allele detection and genotype calling were performed using the ABI 7700 and Sequence Detection Software (Applied Biosystems). All calls scored at least 95% quality values and were verified by 100% recall on ~20% of samples that were re-tested for quality control.

IMAGE ACQUISITION, PROCESSING, AND ANALYSIS
Magnetic resonance imaging images were acquired using a 3-T Allegra System (Siemens, Erlangen, Germany). Whole-brain structural T1-weighted magnetization-prepared rapid gradient-echo (MPRAGE) images were acquired for each subject (FOV = 256 mm; 256 × 256 matrix; 1 × 1 mm in-plane resolution, 1.25 mm thick axial slices, 1 average). All MPRAGE images were processed using SPMB1 on MATLAB 2010b2.

Voxel-Based Morphometry (VBM) was performed using the DARTEL toolbox for SPM (Ashburner and Friston, 2000; Ashburner, 2007). All default settings were used except where noted otherwise. Images were aligned into AC/PC orientation prior to segmenting into gray matter, white matter, and cerebrospinal fluid. All participants’ gray and white matter images were then simultaneously registered together to create a study specific template to reduce between-participant variability. The template was then used to normalize all images into the standard Montreal Neurological Institute (MNI) space using the “DARTEL Normalize to MNI Space” program, utilizing the “preserve amount” option to retain the volumetric data of the original images. The images were smoothed using a Gaussian kernel with 8 mm full-width half maximum (FWHM). For statistical analyses, masks for the left and right entorhinal cortex were created from the Juelich Histological Atlas (Eickhoff et al., 2005). The mean gray matter volumes were then extracted from the participants MNI aligned gray matter images with both masks. Lastly, to account for global brain volume differences, intracranial brain volume for each participant was used to normalize extracted gray matter volumes. Intracranial brain volume was calculated by combining the total brain volumes found in native space gray matter, white matter, and cerebrospinal fluid images for each participant. Left (p = 0.3028, p = 0.5027) and right (p = 0.2231, p = 0.2118) extracted gray matter volumes for the entorhinal and primary visual cortex, respectively, were normally distributed according to the Shapiro-Wilk test; therefore, parametric statistics were conducted.

RESULTS

GENOTYPING
We isolated and purified DNA from 57 participants to genotype for two genes associated with increased risk of late onset AD: APOE and APOJ. The following numbers of subjects per group were included in analyses: ε2/ε2 (2 subjects), ε2/ε3 (6 subjects), ε3/ε3 (40 subjects), ε3/ε4 (9 subjects) (Table 1). Because the ε2 allele is associated with a protective effect from AD, analyses were conducted with and without ε2-carriers. There were two subjects with the ε2/ε4 genotype, and results from these two subjects were excluded from all analyses. The distribution of APOE genotypes was as expected for the United States, with allele frequencies of 0.064 (ε2), 0.783 (ε3), and 0.154 (ε4) (Eisenberg et al., 2010). Of these subjects, there were 15 APOJ-ε3/C/C subjects, 33 APOJ-ε3/T/T subjects, and 9 APOJ-ε3/C/T subjects. Both of the excluded subjects with the APOE-ε2/ε2 genotype also had the APOJ-ε3/T/T genotype, and were excluded from all analyses. The distribution of APOJ genotypes was also as expected based on previous studies, with

| Genotype    | Sex | Age  | O.R. APOE, APOJ | Risk score |
|-------------|-----|------|----------------|------------|
| APOE-ε3/APOJ-C | M: 5; F: 3 | 19.8 ± 1.5 | 4.3, 1.22 | 1.657 |
| APOE-ε4/APOJ-C | M: 1; F: 0 | 19 ± 0 | 4.3, 1 | 1.459 |
| APOE-ε3/APOJ-C | M: 6; F: 2 | 23.8 ± 6.9 | 0.6 or 1, 1 | 0 |

Values for age represent the mean ± standard deviation. Odds ratios (O.R.) are normalized to APOE-ε3 and non-APOJ-C, making these values “1.” Risk scores shown are sums of the natural log of the odds ratios. Non-APOE-ε4 group includes APOE-ε2 carriers that have O.R. of 0.6.
allele frequencies of 0.447 (T) and 0.553 (C) (Golenkina et al., 2010; Table 1).

**MRI**

To test the hypothesis that the APOE-ε4 and APOJ-C risk alleles alter the structure of a brain region affected early in AD pathogenesis (Hyman et al., 1984; Gomez-Isla et al., 1996; Braak et al., 2011), we extracted gray matter volumetric measurements within the left and right entorhinal cortical regions of interest for each genotype group. We then conducted a priori t-tests to interrogate the relationship of each polymorphism with entorhinal cortex volume. A comparison of APOE-ε4-positive vs. APOE-ε4-negative individuals, collapsed across APOJ genotype, revealed significantly greater right entorhinal cortex volume for APOE-ε4 carriers by 8.47%, \( t_{(55)} = 2.29, p = 0.0259 \) (Figure 1, *p < 0.05). This effect persisted when APOE-ε2 carriers were removed from analyses, \( t_{(47)} = 2.185, p = 0.0339 \). Differences in left entorhinal cortex volume in APOE-ε4 carriers compared to non-carriers did not reach statistical significance, \( t_{(55)} = 1.261, p = 0.2126 \) (Figure 1). To examine the effect of APOJ-C in the absence of the APOE-ε4 allele, we grouped non-APOE-ε4 carriers by APOJ-C status (APOJ-C vs. non-APOJ-C-carriers). This comparison revealed that, among non-APOE-ε4-carriers, APOJ-C carriers had greater left entorhinal cortex volume by 12.33%, \( t_{(46)} = 2.05, p = 0.0458 \), and greater right entorhinal cortex volume by 8.16%, \( t_{(46)} = 2.03, p = 0.0485 \) (Figure 2, *p < 0.05). This effect persisted when APOE-ε2 carriers were removed from analyses for the right entorhinal cortex (\( t_{(38)} = 2.03, p = 0.0492 \)), but not the left entorhinal cortex (\( t_{(38)} = 1.89, p = 0.067 \)).

Based on a putative shared biological pathway, we hypothesized that AD risk factors APOE-ε4 and APOJ-C work together to alter brain structure in young adults. We explored the possibility of a combined effect of APOE and APOJ, although the interpretation is somewhat limited by the small number in one of the groups (APOE-ε4, APOJ-non-C; Table 1). A t-test of the highest risk group (APOE-ε4, APOJ-C, \( n = 8 \)) vs. the lowest risk group (non-APOE-ε4, non-APOJ-C, \( n = 6 \)) reveals that greater AD risk is associated with greater right entorhinal cortex volume by 13.89%,
DiBattista et al. | AD risk and entorhinal cortex volume

When including APOE-ε2 carriers in the analyses, this effect on the right entorhinal cortex persists, $t_{(20)} = 2.12, p = 0.0464$, without changing the effect on the left entorhinal cortex, $p > 0.1$. To directly investigate the combined effect AD risk, we tested whether a “risk score” variable was predictive of entorhinal cortex volume. Risk score was weighted by each risk allele’s odds ratio for AD (Bertram et al., 2007; Carrasquillo et al., 2010; Table 1). Specifically, risk score was calculated based on APOE and APOJ genotype by combining the natural log of the odds ratio for each participant to create a single risk score per participant. Values for the two risk alleles were added to generate an additive risk score. This risk scores then served as a regressor for volumetric measurements. The additive risk score was associated with higher right entorhinal cortex volume, $\beta = 5.10, F_{(55)} = 5.47, p = 0.023$, but not left entorhinal cortex volume, $p > 0.1$. This effect persisted as a strong trend in the absence of the APOE-ε4/non-APOJ-C group, $\beta = 4.36, F_{(54)} = 3.89, p = 0.0537$. As a control measure, we also measured gray matter volume in one of the last areas affected by AD (primary visual cortex, V1). As anticipated, neither left ($\beta = 0.3313, p = 0.9117$) nor right ($\beta = -0.6976, p = 0.8168$) V1 volumes were correlated with risk score. Moreover, no APOE-genotype associated differences were observed in the left ($p = 0.8115$) or right ($p = 0.8446$) V1. Overall, these results suggest the possibility that AD risk-related genes APOE and APOJ additively affect brain volume in young people within the entorhinal cortex.

**DISCUSSION**

Apolipoprotein E is the strongest genetic risk factor for AD, and the entorhinal cortex is one of the earliest brain regions to develop neuropathological lesions and atrophy in AD (Hyman et al., 1984; Gomez-Isla et al., 1996; Braak et al., 2011). Because pathogenesis of AD begins as early as two decades prior to the presentation of clinical symptoms (Bateman et al., 2012), it is plausible that a series of genetically-induced differences in brain structure—such as entorhinal cortex volume—could accumulate with aging to increase vulnerability to AD later in life. Here, we assayed entorhinal cortex volume in a cohort of young adults to directly investigate whether APOE and APOJ genetic AD risk alters the structure of this region in early adulthood. Apolipoprotein E-ε4 carriers exhibited greater entorhinal cortex volume in the right hemisphere (Figure 1), and further analysis revealed that the APOJ-C genotype was associated with higher bilateral entorhinal cortex volume in APOE-ε4 non-carriers (Figure 2). The highest risk group (APOE-ε4, APOJ-C) exhibited greater entorhinal cortex volume compared to the lowest risk group (non-APOE-ε4, non-APOJ-C) (Figure 3). When additive odds ratios of APOE and APOJ served as regressors for volumetric measurements, higher disease risk was associated with greater right entorhinal cortex volume.

Volumetric studies report conflicting results when examining MTL volume in APOE risk carriers depending on the experimental parameters. For instance, one study of infants 1–3 months old with family histories of schizophrenia found APOE-associated differences in temporal lobe volume, including the hippocampus and entorhinal cortex (Knickmeyer et al., 2013). However, this effect was not seen in a follow up study with 6–25 month old infants with no family history of schizophrenia (Dean et al., 2014). Similarly, while some evidence has suggested that healthy APOE-ε4 positive adults exhibit decreased bilateral hippocampal volume (O’dwyer et al., 2012) and gray matter density in the right medial temporal region (Wishart et al., 2006), another study in young adults reported that APOE-ε4 carriers showed relative increases in volume in the vicinity of the hippocampus (Alexander et al., 2012). Further contributing to the controversy, other studies have suggested no differences in MTL volume by APOE genotype (Mondadori et al., 2007; Filippini et al., 2009; Dennis et al., 2010; Samuraki et al., 2012; Stein et al., 2012; Matura et al., 2014). Less research has focused on the lesser AD risk factor, APOJ, and its effect on MTL volume. The limited extant research has suggested no difference exists in the MTL by APOJ genotype (Bralten et al., 2011; Stein et al., 2012). A meta-analysis of GWAS including over 7000 cognitively normal subjects.
showed that APOJ genotype was not significantly associated with hippocampal volume (Stein et al., 2012). However, this study did not focus on young adults or target the entorhinal cortex specifically. While the APOJ-C risk allele has no significant effect on gray matter volume by whole brain analyses in young adults, a related risk gene, CR1, was associated with smaller local gray matter volume in the entorhinal cortex in a prior study (Bralten et al., 2011).

The inconsistency of extant evidence could be due to differences in age, gender, exclusion criteria, statistical methods, family history, and how each region of interest was defined across studies. Another explanation may be that the entorhinal cortex is a relatively small region within the MTL, and few studies explicitly target the entorhinal cortex. Thus, it is possible that changes in entorhinal cortex volume are not large enough to alter volume of the MTL as a whole. By specifically targeting the entorhinal cortex in our study, we were able to detect differences in this relatively small MTL structure that may have otherwise been below the threshold for detection.

Our results indicate that the effects of APOE and APOJ may be stronger in the right hemisphere. Medial temporal lobe asymmetry has been linked with AD and disease progression. For instance, APOE-ε4 carriers have thinner left entorhinal cortex compared to the right, while those without APOE-ε4 show this asymmetry in the presence of AD pathology (Donix et al., 2013). Individuals with subjective memory impairment had reduced volumes of the hippocampus and entorhinal cortex bilaterally (Striepens et al., 2010). However, APOE-ε4 carriers without this impairment performed better on episodic memory tests and had larger right hippocampal volumes, as opposed to those with impairment performing worse with smaller right hippocampal volumes (Striepens et al., 2011). Interestingly, differences in asymmetry were also reported in delusional AD patients with greater right temporal horn sizes than left, while non-delusional patients did not show this asymmetry (Geroldi et al., 2000). Although asymmetry effects have not yet reported for APOJ, it is possible that APOE may work in conjunction with APOJ to induce asymmetry.

With aging, reductions in MTL volume in the hippocampus and entorhinal cortex are correlated with cognitive decline in the elderly (Bergfield et al., 2010; Raz et al., 2010; Varon et al., 2011). However, reductions in gray matter volume during the course of brain development in adolescence and early adulthood, correlate with increased synaptic pruning (Gogtay et al., 2004). Thus, increased entorhinal cortex volume during this developmental window could indicate a deficit in neural efficiency. Our study involved individuals of an average age of 21.8 years old, all of whom are at these later stages of brain development. Prior evidence has linked the APOJ-C risk allele to abnormal brain development through decreased white matter integrity (Braskie et al., 2011) and subsequent altered coupling between the hippocampus and prefrontal cortex during memory processing, mirroring disrupted connectivity in patients (Erk et al., 2011). Other evidence has also linked APOE-ε4 to abnormal brain structural and functional development in young risk allele carriers, suggesting that APOE and APOJ risk may impede the pruning process in the entorhinal cortex.

Alternatively, these findings could contribute to evidence suggesting that the APOE and APOJ risk genes confer an evolutionary advantage early in life, but confer a disadvantage later in life by increasing AD risk. This antagonistic pleiotropy hypothesis of APOE and APOJ risk has been proposed in other contexts (e.g., see Tuminello and Han, 2011; Stevens et al., 2014). College-aged young adults carrying the APOE-ε4 allele have an advantage in verbal fluency, decision making, and memory (Zetterberg et al., 2009; Marchant et al., 2010; Jochemsen et al., 2012; Rusted et al., 2013; Green et al., 2014), but these advantages disappear by middle age and give way to impairment in old age. These beneficial effects early in life could be due in part to increased volume in the entorhinal cortex, allowing for more effective processing of memory-associated information.

Finally, larger entorhinal cortex volume in APOE and APOJ risk carriers could indicate more neuroinflammation in the entorhinal cortex of young adults. It has been postulated that APOE-ε4 may increase neuroinflammation during aging, thus increasing susceptibility to dementia later in life (e.g., for review, see Guo et al., 2004; Kim et al., 2009). Several studies have also linked APOJ-C risk to decreased CLU levels (Schurmann et al., 2011), which are thought to serve an anti-inflammatory role (Savkovic et al., 2007). Glia can contribute to half of brain volume changes (Snell, 2009), and studies have shown that APOE-ε4 is associated with increased neuroinflammation (Guo et al., 2004; Chen et al., 2005; Maezawa et al., 2006; Zhu et al., 2012). Because the entorhinal cortex is one of the earliest affected brain areas in AD, it is possible that the increase in entorhinal cortex volume could be due to a deficit in APOE and APOJ carriers to control neuroinflammation in the young adult brain.

Overall, our findings in a young adult cohort indicate an additive effect of two of the strongest AD risk factors on a brain locus at the epicenter of AD pathogenesis. Entorhinal cortex volume increased as a function of increasing APOE and APOJ genetic AD risk. These results contribute to a growing literature characterizing genetic markers of AD risk in the young brain, long before the first overt signals of Alzheimer’s appear. Thus, these findings inform our understanding of the role of these genetic risk factors in the normal brain, and contribute to the development of biomarker targets for future preventive AD therapies.

ACKNOWLEDGMENTS
This work was supported by NIH R01 AG035379, P01 AG030128 (G. William Rebeck), grants from Partners in Research and the American Legacy Foundation (Adam E. Green), and NIH NINDS 5T32NS041218 (Amanda M. DiBattista). Samples from the National Cell Repository for Alzheimer’s Disease, which receives government support under a cooperative agreement grant U24 AG21886 awarded by the National Institute on Aging, were used in this study.

REFERENCES
Alexander, G. E., Bergfield, K. L., Chen, K., Reiman, E. M., Hanson, K. D., Lin, L., et al. (2012). Gray matter network associated with risk for Alzheimer’s disease in young to middle-aged adults. Neurobiol. Aging 33, 2723–2732. doi: 10.1016/j.neurobiolaging.2012.01.014
Ashburner, J. (2007). A fast diffeomorphic image registration algorithm. Neuroimage.38, 95–113. doi: 10.1016/j.neuroimage.2007.07.007
Marchant, N. L., King, S. L., Tabet, N., and Rusted, J. M. (2010). Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers. *Neuropsychopharmacology* 35, 1090–1096. doi: 10.1038/nnpp.2009.214

Matura, S., Pruvolovic, D., Jurcoane, A., Hartmann, D., Miller, J., Scheibe, M., et al. (2014). Differential effects of the ApoE4 genotype on brain structure and function. *Neuroimage* 89, 81–91. doi: 10.1016/j.neuroimage.2013.11.042

Mondadori, C. R., de Quervain, D. J., Buchmann, A., Mustovic, H., Wollmer, M. A., Schmidt, C. F., et al. (2007). Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. *Cereb. Cortex* 17, 1934–1947. doi: 10.1093/cercor/bhl103

Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W., and Pitas, R. E. (1994). Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. *Science* 264, 850–852. doi: 10.1126/science.8171342

O’Bye, L., Lambertton, E., Matura, F., Tanner, C., Scheibe, M., Miller, J., et al. (2012). Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. *PLoS One* 7:e48895. doi: 10.1371/journal.pone.0048895

Raz, N., Ghisletta, P., Rodrigue, K. M., Kennedy, K. M., and Lindenberger, U. (2010). Trajectories of brain aging in middle-aged and older adults: regional and individual differences. *Neuroimage* 51, 501–511. doi: 10.1016/j.neuroimage.2010.03.020

Reinvang, I., Espeseth, T., and Westlye, L. T. (2013). APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer’s disease. *Neurosci. Biobehav. Rev.* 37, 1322–1335. doi: 10.1016/j.neubiorev.2013.05.006

Risacher, S. L., Shen, L., West, J. D., Kim, S., Mcdonald, B. C., Beckett, L. A., et al. (2010). Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. *Neurobiol. Aging* 31, 1401–1418. doi: 10.1016/j.neurobiolaging.2010.04.029

Rusted, J. M., Evans, S. L., King, S. L., Dowell, N., Tabet, N., and Tofts, P. S. (2013). APOE e4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures. *Neuroimage* 65, 364–373. doi: 10.1016/j.neuroimage.2012.10.010

Samuraki, M., Matsuura, L., Chen, W. P., Shima, K., Yanase, D., Takeda, N., et al. (2012). Glucose metabolism and grey-matter concentration in apolipoprotein E epsilon4 positive normal subjects. *Neurobiol. Aging* 33, 2321–2323. doi: 10.1016/j.neurobiolaging.2011.11.020

Savkovic, V., Gantzner, H., Reiser, U., Selig, L., Gaiser, S., Sack, U., et al. (2007). Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. *Biochem. Biophys. Res. Commun.* 356, 431–437. doi: 10.1016/j.bbrc.2007.02.148

Schurmann, B., Wiese, B., Bickel, H., Weyerer, S., Riedel-Heller, S. G., Pentzek, M., et al. (2011). Association of the Alzheimer’s disease clusterin risk allele with plasma clusterin concentration. *J. Alzheimers Dis.* 25, 421–424. doi: 10.3233/JAD-2011-110251

Shen, L., Kim, S., Risacher, S. L., Nho, K., Swaminathan, S., West, J. D., et al. (2010). Whole genome association study of brain-wide imaging phenotypes for progression of cognitive impairment. *Dement. Geriatr. Cogn. Disord.* 31, 276–283. doi: 10.1159/000324711

Wishart, H. A., Saykin, A. J., Mcallister, T. W., Rabin, L. A., Mcdonald, B. C., Flashman, L. A., et al. (2006). Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. *Neurology* 67, 1221–1224. doi: 10.1212/01.wnl.000028079.00472.3a

Zetterberg, H., Alexander, D. M., Spandidos, D. A., and Blennow, K. (2009). Additional evidence for antagonistic pleiotropic effects of APOE. *Alzheimers Dement.* 5:75. doi: 10.1016/j.jalz.2008.10.005

Zhu, Y., Nwabuisi-Heath, E., Dumanis, S. B., Tai, L. M., Yu, C., Rebeck, G. W., et al. (2012). APOE genotype alters glial activation and loss of synaptic markers in mice. *Glia* 60, 559–569. doi: 10.1002/glia.22289

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.